Suven Life Sciences has received European product patent for its clinical candidate SUVN-502, valid until June 2023 for treatment of neuro-generative disorders

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products. The European Patent Office (EPO) granted the Product Patent, EP 1581492 to Suven’s clinical candidate SUVN-502 which is valid until June 2023. EP 1581492 is an exclusive intellectual property (IP) of Suven and was achieved through the internal discovery research efforts.

The drug candidate is being developed for treatment of neuro-generative disorders like Alzheimer's disease, attention deficit hyperactivity disorder, memory impairment associated with ageing and Schizophrenia. Potential market opportunity for these indications is more than 18 billion dollars globally.

With EP 1581492, Suven has four European Product Patents granted and all of them have been validated in all the 37 member countries of Europe including major markets like Germany, Switzerland, Denmark, Spain, France, The United Kingdom, Italy, Netherlands, Poland, Sweden and Finland.

In addition to this Suven has obtained product patents from USA (4), India (4), Australia (2), Eurasia (2), Korea (2), Mexico (2), New Zeeland (2), and Singapore (2).

The granted claims of all the above patents include the class of selective 5-HT compounds discovered by Suven and are being developed for the treatment of debilitating Central nervous system (CNS) disorders such as Alzheimer’s disease, ADHD, depression, Huntington’s disease, MCI,  memory impairments associated with aging, Parkinson’s disease, Schizophrenia, vascular dementia and  obesity.